1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
InnSuites Hospitality Trust said NYSE American accepted its compliance plan and granted a plan period through December 24, 2027. The Trust is not currently in compliance with NYSE American continued listing standards, but its listing continues under the extension, and staff could start delisting proceedings if the Trust does not meet the standards or make progress under the plan.
NYSE American notice received September 10, 2026; plan period runs through December 24, 2027
Trust increased stockholders' equity by $3 million on August 19, 2026, as one step toward compliance
Consolidated net income for the Fiscal First Quarter was $74,702, up 48% from the prior year quarter
Filing states there is no assurance the Trust will regain compliance or complete any proposed transaction
Boxlight received a Nasdaq Hearings Panel decision on September 2, 2026 that it has regained compliance with the $2.5 million stockholders' equity requirement and may continue listing on Nasdaq. The Panel also imposed a one-year monitoring period, so any future Nasdaq rule noncompliance could lead directly to a delisting determination without a cure period.
Panel decision dated September 2, 2026 found compliance with the $2,500,000 stockholders' equity rule (Rule 5550(b)(1)).
Compliance plan relied on a Series D preferred financing: $4.8 million raised in Tranche One on August 5, 2026, with about $6.6 million in net proceeds for the full PIPE transaction.
One-year Discretionary Panel Monitor effective August 17, 2026; any new noncompliance may lead to a Delist Determination Letter.
Review of the decision may be requested within 15 calendar days, subject to a $15,000 fee.
QVC Group filed its Monthly Operating Report for July 2026 with the U.S. Bankruptcy Court for the Southern District of Texas, as required during its Chapter 11 case. The report shows a July net loss of $42.3 million on $295.8 million of gross sales, and a net deficit of $5.8 billion. The company says the figures are unaudited, preliminary, and not meant for investment decisions, so they may change materially.
July 2026 gross income (sales, net of returns and allowances): $295.8 million
July 2026 profit (loss): $42.3 million loss; cumulative column shows a $104.0 million loss
Cash balance at end of July 2026: $200.6 million; total liabilities: $7.9 billion
Report filed September 11, 2026; Plan became effective August 6, 2026 after July 20 court confirmation
Cardiff Oncology and Nerviano Medical Sciences agreed on September 14, 2026 to settle their pending litigation, with both parties dismissing the case with prejudice and exchanging mutual releases, and no monetary payment made between them. The companies also amended the 2017 license agreement for onvansertib, changing exclusivity, royalty, milestone, governance and assignment terms, which matters to shareholders because it reshapes the economics and conditions of the company's lead asset.
Settlement and Amendment dated September 14, 2026; the Amendment takes full effect when the case is dismissed with prejudice.
No monetary payment was made by either party to resolve the litigation, and neither party admitted liability.
Amendment adds an additional license fee on annual net sales of products practicing a valid Company patent claim, in lieu of the existing royalty.
If Cardiff assigns the license, including by merger or change of control, before Phase III data readout, it would owe Nerviano a percentage of transaction proceeds based on Phase III dosing timing.
SmartKem, Inc. received notice from Nasdaq on September 10, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, and the Staff has closed the matter. The company had received a deficiency notice on March 5, 2026, so the stock has avoided a listing-related threat that had been pending since then.
Nasdaq Staff notified SmartKem on September 10, 2026 that it regained compliance with Listing Rule 5550(a)(2).
The closing bid price was at or above $1.00 per share for 13 consecutive business days, from August 21 through September 9, 2026.
The company first received the minimum bid price notice from Nasdaq on March 5, 2026.
The FDA granted Breakthrough Therapy designation to Armata's AP-SA02, an intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia. The company says the designation is intended to expedite review and that AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, but the filing discloses no revenue, earnings or financing figures.
FDA granted Breakthrough Therapy designation to AP-SA02 for complicated bacteremia caused by MSSA or MRSA, announced September 14, 2026.
AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations.
In the Phase 1b/2a diSArm study, 100% of AP-SA02 patients maintained clinical response without relapse at 28 days after completion of BAT, compared with 75% on placebo plus BAT.
The company plans a Phase 3 superiority study, anticipated to start in the second half of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.